key: cord-0745125-mtnov7xh
authors: Machhi, Jatin; Shahjin, Farah; Das, Srijanee; Patel, Milankumar; Abdelmoaty, Mai Mohamed; Cohen, Jacob D.; Singh, Preet Amol; Baldi, Ashish; Bajwa, Neha; Kumar, Raj; Vora, Lalit K.; Patel, Tapan A.; Oleynikov, Maxim D.; Soni, Dhruvkumar; Yeapuri, Pravin; Mukadam, Insiya; Chakraborty, Rajashree; Saksena, Caroline G.; Herskovitz, Jonathan; Hasan, Mahmudul; Oupicky, David; Das, Suvarthi; Donnelly, Ryan F.; Hettie, Kenneth S.; Chang, Linda; Gendelman, Howard E.; Kevadiya, Bhavesh D.
title: Nanocarrier Vaccines for SARS-CoV-2
date: 2021-01-09
journal: Adv Drug Deliv Rev
DOI: 10.1016/j.addr.2021.01.002
sha: abbe5d95c233a38d0009c3bae4741ee6a275a365
doc_id: 745125
cord_uid: mtnov7xh

The SARS-CoV-2 global pandemic has seen rapid spread, disease mobidities and death associated with substantive social, economic and societal impact. Treatments rely on re-purposed antivirals and immune modulatory agents focusing on attenuating the acute respiratory distress syndrome. No curative therapies exist. Vaccines remain the best hope for disease control and elimination and the principal global effort with success now being realized. Herein, we summarize those developments with a focus on the role played by nanocarrier delivery.

In late 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged and on March 11, 2020 it was declared a pandemic [1] . Clinical outcomes ranged from asymptomatic infection to severe acute respiratory distress syndrome (ARDS) and death. The World Health Organization (WHO) named the resultant disease complex coronavirus disease 2019 [2, 3] . COVID-19 has negatively impacted the global socioeconomic well-being of the world's population. Global lack of health care, infrastructure, and preparedness has intensified the pandemic's impact [4] . Viral detection, mobilization and control of person-to-person spread served as the primary means for containment. Induction of effective host antiviral immunity against SARS-CoV-2 comes secondary to infection [5, 6 ]. An uncontrolled innate immune response is the signature of virus-induced pro-inflammatory responses for an ARDS.

Alveolar macrophage inflammation disrupts cell and tissue homeostasis leading to endorgan lung disease [7, 8] . In the absence of a vaccine, virus-induction of adaptive humoral immune responses can attenuate disease progression [9] .

A vaccine can elicit protective antiviral responses against SARS-CoV-2. Short of containment it is the most effective means to prevent infection in susceptible people [10] . To this end, there are more than 137 vaccine candidates in development and 23 in Phase 2 or 3 trials [11, 12] . One promising candidate BNT162b2 is already approved while several others are soon to be approved for prevention in the United States of sustenance [97] . T cell responses persist > 10 years in those who recovered from MERS-CoV and SARS-CoV infections. Whether these are protective is not known [59] .

It was demonstrated by in silico models that immunity against SARS-CoV-2 could be transient. If operative, there is a likelihood that, like influenza A and B viruses, SARS-CoV-2 may lead to biennial or annual outbreaks. Therefore, a need exists to determine the extent and duration of immunity against SARS-CoV-2 [98] . This need is further complicated because the antibody response that is mounted against SARS-CoV-2 is not always accompanied by viral clearance [99] . Antibody levels vary based on age [100] , re-infection rates [101] , and length of illness. Cases with SARS-CoV-2 reinfection have been reported and virus strains with different genome sequences in a single person [102] . Re-infection is distinguished from relapse and prolonged viral shedding [103] . Although the number of re-infection is limited compared to new infections, re-infection is linked to how long-term neutralizing antibody titers are sustained [104] . Emergence of mutant strains of SARS-CoV-2 and viral epitope stability affect re-infections [105] . COVID-19 has a lower fatality rate than SARS-CoV and MERS-CoV infections but higher than flu (~3% versus 0.1%) [106] . However, since SARS-CoV-2 is more contagious than the flu, and has spread rapidly across the globe, the 1.5 million deaths from COVID-19 in the past 10 months has already exceeded the total number of deaths from the last five flu seasons [92, 107, 108] . Viral infections with low fatality rates enable the host to mount an immune response, that create selection pressure for the emergence of mutant virus strains [109] . Considering re-infection, limited immunity, virus mutations and need for herd immunity underlies the importance of vaccination.

J o u r n a l P r e -p r o o f

Bacteria and viruses are pathogens that commonly elicit disease [110] . For a successful pathogen to survive and grow, it must have ability to: (i) inhabit the host; (ii) avoid or circumvent host immune responses; (iii) grow by affecting host biological machineries to its benefit; and (iv) transmit itself from one host to another [110, 111] . Viral infections possess nucleic acids surrounded by a protein shield. Viruses can also be classified based on various criterias including genetic material, number of nucleic acid strands, envelope, shape, and structure [111, 112] . Some viruses contain an envelop whereas some do not. For example, adenoviruses and adeno-associated viruses (AAVs) are non-enveloped viruses, whereas herpesvirus and coronavirus are enveloped. The viral envelope-membrane, when present, consists of lipid and glycoproteins and it is acquired during detachment of virus from the host cell [113] .

Upon exposure, body's immune system mount a specific response enabling the host to be protected upon re-exposure [110, 113] . Vaccines harness the body's immune responses providing protective immune responses against infection. Vaccines are broadly available against tuberculosis, diphtheria, tetanus, pertussis, haemophilus influenzae type B, cholera, typhoid, streptococcus pneumoniae and viral infections that include influenza, hepatitis, diphtheria, measles, mumps, and polio. Efforts are still under development for chikangunya, dengue, malaria, cytomegalovirus and leishmaniasis [114] .

SARS-CoV-2 vaccine development had now achieved USA FDA approval [12] . What is now available is able to induce long-lasting viral neutralizing antibodies that prevent viral attachment (through a ACE2 receptor) to epithelial cells in the mucosal layers and type J o u r n a l P r e -p r o o f II pneumocytes [16, 115] . Vaccine should also induce sustained humoral and cellular immune responses which would generate long-lasting memory T cell responses.

Further features of an effective vaccine include ease of administration (single dose, mucosal), storage, production, and scale-up [15, 116] . The spike (S), nucleocapsid (N), membrane (M), and envelope (E) glycoproteins are known immunogenic proteins for SARS-CoV-2. The spike S protein is the major target for vaccine development, as it is involved in the viral entry via ACE2 receptors [115, 117] . Several COVID-19 vaccine candidates have or are being developed. Viral vaccines against SARS-CoV-2 include:

(i) live and attenuated; (iii) inactivated; (iv) nucleic acids; (v) viral vectors (self-and nonreplicating); and (vi) protein and subunits; (Fig. 1) . These can be propagated in animals, chicken embryos, and cell cultures and tissues [118, 119] . Currently vaccines are approved for marketing in different countries to control more than 30 infectious diseases [120] . Vaccines are monovalent, effective against a single antigen or a pathogen (Rotarix) and polyvalent/multivalent, effective against strains of the same pathogen (RotaTeq) [116, 121] .

i. Live attenuated: These use live viruses to elicit protective immune responses. India and China use a live virus vaccine to boost small pox immunization. They expose people to material obtained from patients infected with a mild virus form [121, 122] . Live vaccine raises the possibility of viral virulence reversal [123] . Therefore, live virus vaccines need be developed by altering the viral genome and selecting non-pathogenic mutant strains incapable of causing disease [124] . Live virus vaccines can also be produced by viral attenuation. These are viruses weakened in their pathogenicity but can elicit antiviral immune responses without causing disease. One of the most widely J o u r n a l P r e -p r o o f used strategy is serial passages of virus in chick embryo fibroblasts and vero cells. This is a well accepted practice for the vaccine development [125, 126] . As the virus replicates through each passage, it loses virulence [119] . Attenuated viral vaccines against measles, mumps, and chickenpox were developed [127] . Another means used to generate live attenuated vaccines involves deletion or viral gene mutation essential for viral growth. These defective viruses cannot replicate in a human host [128] but can induce immune responses [129] . The first replication-defective live viral vaccine was developed against herpes simplex virus-1 (HSV-1) [130, 131] .

Replication-defective HSV-2 missing the genes essential for viral DNA synthesis was produced [132] . Another approach is to grow virus at reduced temperatures. Attenuated viruses can also be developed by inserting viral proteins into an attenuated coldadapted virus [133] . Live attenuated virus induce no or limited infection [134] . However, these strains show an ability to induce herd immunity by shedding of viral particles and by host to host transmission. Live-attenuated vaccines are capable of eliciting illness in the immunosuppressed individuals [123] . To overcome this limitation, codon deoptimization is used. Codon deoptimization vaccines are completely safe due to substitution of several nucleotides from the virus coding sequence [135, 136] . Recently, live attenuated vaccine was produced against Ebola and found to be > 97% effective in J o u r n a l P r e -p r o o f 90,000 individuals [137] . Currently, Griffith University in collaboration with Indian Immunologicals Ltd. developed codon deoptimized live attenuated vaccine for SARS-CoV-2. The vaccine can induce long lasting protective immunity after single dose without cross reactivity to MERS and SARS-CoV [138] . Existing vaccine manufacturing facilities are capable to develop live attenuated vaccine for large scale production [139] .

ii. Inactivated viruses: These viruses are inactivated by radiation, heat, and chemicals such as binary ethyleneimine and formalin. This leads to an inability to cause illness.

However, inactivated viruses maintain the ability to induce host immunity that recognize and destroy pathogens. This vaccine type contain viral particles from inactivated virus and hence do not develop pathogenicity [116, 140] with the support of the Korean Government. Currently, recruitment of 120 healthy volunteers is under progress to initiate a Phase 1 clinical trial [161] .

Vector-based vaccines are kind of live attenuated vaccines which use available viral vectors with known safety profiles. Vectors deliver specific gene that encodes for a specific antigen. When viral vectors are injected, a gene of interest transcribes a specific antigenic protein, and thereby elicits immunity. Vectors do not require adjuvants and are capable of eliminating virus-infected cells by inducing a cytotoxic T cell (CTL) responses [162] [163] [164] . Existing viral vectros can be divided into two categories: replicating (replication-competent) and non-replicating (replication-deficient).

The replicating viral vector produces infectious viruses capable of infecting target cells to produce viral antigens. The most widely used replicating vectors include the measles and the vesicular stomatitis virus, both are single-stranded, and antisense RNA viruses able to deliver heterologous antigens that can induce both cellular and humoral immune responses [165] . The major advantage of the measles virus vector (MVV) is that it elicits life-long cellular and humoral immunity. Due to helical structure of measles virus, J o u r n a l P r e -p r o o f vectors prepared from it can tolerate insertion of genes over a size of 6Kb and vectors are stable even after multiple passages [166] . [167, 168] . Recombinant MVV is also known for more specific targeted antigen delivery to the macrophages and can be used as multivalent vector for HIV-1, West Nile virus, and others [169, 170] . In contrast, non-replicating viral vectors include adenovirus, adeno-associated virus (AAV), herpes virus, and alpha virus. Originally, they were developed from simian adenoviruses and some other pathogens such as Ebola virus, RVFV, and Zika virus [171] . Adenovirusbased viral vectors are most commonly used. The E1A and E1B genomic regions of adenovirus are replaced by genes encoding target viral antigens [172] . Adenoviral vectors can express gene inserts of size over 8Kb, and hence can be used to generate multivalent vaccines [173] . Adenoviral vector Ad5 can provoke CD8 T cells and strong antiviral responses and provide ease of large scale production [174, 175] . Other adenovirus-based vectors (Ad26 and Ad35) are candidates for HIV-1 vaccine due for their abilities to infect functional memory T cells [176, 177] . The key advantages of non-J o u r n a l P r e -p r o o f replicating adenovirus vectors include ease of genetic alterations, stability, safety, higher growth rate, strong immune response, and thermostability [178] .

In spite of structural similarities, AAV display improved stability over adenoviruses. The protein coverings of a virus (capsid) and specific activating protein assembly facilitate their targeted delivery potential [179, 180] . The recombinant AAV vectors (rAAV) are superior over native AVV where the Rep and Cap genes of AAV are replaced with the genes encoded for target antigens to elicit neutralizing antibodies [181] . AAV-based vectors are used as a tool in gene therapy for the treatment of various disorders like muscular atrophy, inherited blindness, and haemophilia [182] . Despite advantages, viral vectors have several limitations. Vector induced immunity is common with this technology that reduces the efficacy of the vaccine. Host genome integtation is another key limitation with viral vector leading to the risk of tumorigenesis. Also certain viral vectors like AAV have low titer production which become limiting step in bulk vaccine production. However, due to highly specific delivery and long lasting immune response after single administration, viral vector platform is still well accepted and in the past this technology has shown successful eradiation of smallpox [162] . Technological developments have increased host immune responses as well as the large-scale production of viral vectors that ease the regulatory requirements of this technology [116] .

Currently, many COVID-19 vaccines are under development with this technology.

AD26 associated vaccine against SARS-CoV-2 showed complete protection in rhesus macaques after infection [183] . Thereafter, a series of AD26 vectors encoding different SARS-CoV-2 spike protein epitopes were developed with encouraging outcomes [184, J o u r n a l P r e -p r o o f 185] . Recently, Russia approved a COVID-19 vaccine Sputnik V exhibiting two different adenovirus vectors (rAd26 and rAd5), both carrying the gene for SARS-CoV-2 S glycoprotein (rAd26-S and rAd5-S) (Fig. 3) .

Developed by Gamaleya Center in Russia, two-vector vaccine, as the name suggests, uses two different vectors (Ad5 and Ad26). Vector development involves the use of S-protein mRNA to generate the complementary DNA, followed by insertion of this S-protein encoding DNA into adenoviral vectors, Ad26 and Ad5. Ad26 vector encoding S-protein was administered as first vaccination followed by a booster dose of Ad5 vector encoding the same S-protein 21 days later. Inside the recipient, these vectors generate the S-proteins, which upon entering the circulation induces protective immunity.

The premature decision was made after the encouraging results of Sputnik V in Phase 1 and Phase 2 clinical trials, with just 38 participants in each study [186] . In Phase 1 study, both rAd5-S and rAd26-S vaccines were found safe and well tolerated for up to 28 days. In Phase 2 study, rAd26 was administered on day 1 followed by a booster dose of rAd5 on day 21 where 100% of the participants showed seroconversion and high SARS-CoV-2 antibody titer than COVID-19 convalescent plasma. Both antigenspecific CD4 and CD8 T cells were observed in all the participants [186] . However, large-scale Phase 2 clinical trial results are needed for US FDA approval and to vaccinate the general population with Sputnik V [187] . Other COVID-19 vaccines developed using this technology include Ad5-nCoV, AZD1222, aAPC, and LV-SMENP-DC. Ad5-nCoV, developed by CanSino Biologics Inc., is the first vaccine to reach Phase 2 clinical trial. In Phase 1 clinical trial, Ad5-nCoV was found well tolerated and immunogenic in 108 participants 28 days post vaccination [188] . In Phase 2 study, single immunization of Ad5-nCoV induced significnat SARS-CoV-2 neutralizing antibodies and immunogenic response in all 508 participants [189] . Ad5-nCoV has already been approved for the military use in the China and currently it is under Phase 3 clinical trial investigation in russia [190] . AZD1222, formerly known as ChAdOx1-S is being developed by the University of Oxford with AstraZeneca. Currently, Phase 2/3 J o u r n a l P r e -p r o o f clinical trila is ongoing but the interim results of Phase 2 study showed better tolerance of AZD1222 in older adults compared to the young adults with equivalent immunogenicity across different age groups 28 days after single booster immunization.

To note, when tested in the animlas, no complete protection against SARS-CoV-2 infection was observed [191] . AZD1222 is the first vaccine candidate being investigated in the Phase 3 clinical trial. Previously, Phase 3 study of AZD1222 was put on hold after suspected serious adverse reactions in the UK trial participants which is now resumed after recommendations of the independent safety review committee and the United Kingdom Medicines and Healthcare Regulatory Agency [192] . AstraZeneca has agreement with Europe's Inclusive Vaccines Alliance to supply 400 million doses of AZD1222 by the end of 2020 [193] . the other viral vaccines [194] . However, like other viral vaccines, protein subunit vaccines have limitations, major one is limited efficacy. In this technology, the isolated antigenic fragment of the pathogen likely denatured that conjugate with untargeted antibodies leading to the diminished efficacy [195] . Hovever, recombinant DNA J o u r n a l P r e -p r o o f technologies have successfully overcome such limitations as evidenced by the approval of first recombinant protein subunit vaccine against hepatitis B which has now controlled the disease to near elimination [196] . It has also open the way for regulatory relaxations for the vaccines developed by this technology [197] . Furhther advancements made in this vaccine technology make them more suitable for the immunocompromised individuals. For the production of recombinant proteins, E.coli [198] [199] [200] and yeasts are used [200, 201] .

Several protein subunit vaccines are marketed against diseases including influenza, HPV, and hepatitis B [202] . To improve immunogenic action of such vaccines, diverse formulations of vaccines with potent adjuvants have been employed [144] . The subunit vaccine for hepatitis B is an example of a single antigen-containing subunit vaccines, whereas influenza vaccine is an example of a subunit vaccine that contains two antigens (haemagglutinin and neuraminidase) [124, 197, 198, 203] . Large scale production of purified antigenic protein is also challenging which can be improved by various expression systems including plant-based [204] . Envelope glycoproteins E1 and E2 of Chikungunya virus (CHIKV) were expressed in insect cells as well as in bacterial expression systems to develop subunit vaccines effective against CHIKV [205] . The subunit vaccines developed from the capsid protein (CP) of astrovirus, protected mink litters against astrovirus infection better than the whole CP [206] . Recombinant subunit vaccines against herpes zoster showed significant reduction in the risk of post therapeutic neuralgia [207, 208] . Currently, several vaccine candidates have been developed using this technology against COVID-19 focused on the SARS-CoV-2 S protein or specific domain within the S protein such as receptor binding domain (RBD).

The University of Queensland in collaboration with GSK and Dynavax is developing stabilized pre-fusion recombinant protein subunit vaccine against SARS-CoV-2 using its Molecular Clamp technology that lock the SARS-CoV-2 specific protein in the threedimentional shape with ability to develop humoral immune response against appropriate viral epitopes [12] . Novavax protein [209] . MigVax Ltd. has developed oral subunit vaccine technology against poultry coronaviruses and now it is developing COVID-19 vaccine with this technology [210] .

Deployment of CTL is a promising vaccine approach for different pathologies. T cell's unique T cell receptors (TCRs) recognize and activate against viral-specific antigens which drive immune responses [211, 212] . Adoptive transfer of virus epitope-specific T cells showed protective immune responses against various viral infections including adenovirus [213] , Epstein-Barr virus (EBV) [214] , human cytomegalovirus (CMV), [215] . Antigen-targeted TCRs have limitations of cross-reactivity and induction of autoimmunity [216] . To overcome such limations, recently combination immunotherapy has been applied for the treatment of various cancers and chronic viral infections where antigen targeted cells are delivered along with other immunemodulators [217] . During viral infection, activated T cells express the programmed death (PD-1) and other inhibitory receptors that make T cells dysfunctional. To overcome such J o u r n a l P r e -p r o o f problems, antigen-targeted T cells should be administered alongside the anti-PD1 antibody, otherwise inhibitory receptors are genetically ablated to better control the viral infection [218] [219] [220] [221] [222] . Another cell-based vaccine approach uses whole cells or cell lysates as a source of antigen or as a platform to deliver antigens. Virus infected cells are irradiated or healthy cells are transfected with a virus to provoke humoral and cellular immune responses where endogenous dendritic cells (DCs) play a vital role in the development of neutralizing antibodies [223] . DCs are potential candidate for the cell-based vaccine. DCs play an intermediate role between the innate and adptive immunity. DCs sense foreign antigens, processs and represent them to the T cells to contribute protective immune responses [211] . Like T cells, DCs can be manipulated ex vivo to confirm antigen specificity. DCs can be modified by different technologies such as loading of DCs with the immunogenic viral protein, transfection with viral protein, or loading with viral mRNA, each strategy induce vaccine of different potency. DCbased vaccines can also be incorporated with the immunomodulatory agents or their gene to improve therapeutic outcomes [224, 225] . DC-based vaccine PROVENGE (sipuleucel-T), loaded with a prostatic acid phosphatase (PAP)-granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein has proven effective in patients with prostate cancer [226] and became the first US FDA approved DC-based vaccine for prostate cancer [227] . limitations. The inactivated and subunit vaccines often exhibit low immunogenicity therefore frequent booster dose administration is required. Also the effectiveness of the nucleic acid vaccines is questionable due to lack of any licenced vaccines for the human use [230, 231] . The globally spread COVID-19 has affected a lrege population of all the ages due to lack of appropriate prophylactic measures. To fullfill the overwhelming demand in COVID-19 pandemic, a vaccine with high immuniogenicity, faster onset of action, low toxicity, and minimal dose injection is primary requiremet. All outcomes can be achieved by incorporating suitable adjuvants. [232] . A formulation or an immunostimulatory reagent which is designed to improve the performance of a vaccine is adjuvant. Adjuvants enhances antigen-specific protective immune responses and targeted antigen delivery of a vaccine and therefore reduce vaccine dose and associated toxicities [233, 234 ]. An ideal adjuvant should offer heterologous antibody response, potential to kill or neutralize diverse pathogens, and effective T cell responses [235, 236] . Moreover, adjuvants should be cheap and widely available with good biodegradable and biocompatible properties [237] . Activation of TLR lead to indiction of robust humoral and cellular immune responses against invading pathogen. Therefore, use of small molecules that activate TCRs on the APCs are frequently incorporated in the vaccine to improve immune responses [238] .

Due to ability to directly interact with the APCs and B cells, TLR agonists amplify the innate and adaptove immune responses [239] . J o u r n a l P r e -p r o o f ii. Aluminium: Aluminium hydroxide or alum is the most commonly used adjuvant in the vaccine formulations. Alum adjuvant has been used in the licenced vaccines for the human use against diphtheria, tetanus, pertussis, and hepatitis [245] . Insoluble aluminium salts were the first generation of vaccine adjuvants founded on the discovery of an alum-precipitated diphtheria toxoid suspension. They show improved immunogenicity compared to soluble toxoid [246, 247] . The performance of aluminium adjuvant, in part, depends on the composit concentration and absorption of the antigen on a preformed aluminium gel [248] . Alum adjuvants form depot at the injection site followed by slow release of the target antigen to enable its prolonged interactions with the APCs. Alum adjuvants also facilitate antigen uptake of the APCs to activate T cell responses [249] . A SARS-CoV viral vaccine sequencialy inactivated by formaldehyde and UV induced high antibody titer against S protein and neutralizing antibodies in the mice whereas the protective effects were improved by the adjuvant aluminium hydroxide [250] . A SARS-CoV inactivated vaccine induced dose dependent neutralizing antibody responses in the mice and protected them from the viral infection. Such protective effects of vaccine were further improved upon addition of alum adjuvant [251] . Alum in combination with CpG oligonucleotide had demonstrated enhanced humoral and cellular responses in the mice immunized with either inactived or S-based or RBD-based MERS-CoV vaccines [252, 253] .

iii. Emulsions: A decade after the discovery of alum-based formulations, emulsion adjuvants were developed by Freund [254] . Emulsions are a dispersion of two or more immiscible liquids composed of oil, emulsifiers, and excipients [255] . which is a novel microcrystalline polysaccharide particle engineered from the delta inulin, potentiated the immunostimulatory potential of co-delivered antigen recombinant SARS-CoV-2 S protein [273] . In BNT162b1, an mRNA COVID-19 vaccine, mRNA itself serve as an adjuvant and therefore allow synchronized delivery of antigen and adjuvant [274] . The lipid nanocarriers used in the formulation of vaccines can also serve as adjuvant. The dicetyl phosphate when incorporated into the nonovaccine against diphtheria toxoid improved the protective immune responses by serving as an adjuvant [275] . Overall, the adjuvants with desired proterties are critical for effective vaccine delivery.

Nanoparticles share size distribution with the viruses and therefore like viruses, [276] , [277, 278] . Following approached are used for antigens and adjuvants codelivery, (i) direct conjugation of antigen and adjuvant, (ii) encapsulation within or decorated onto the nanoparticle, and (iii) use of delivery vehicle as adjuvant. Nanovaccine formulations can enhance antigen stability by maintaining native confirmation and protect them from proteolytic degradation [279] . In the promising mRNA based COVID-19 nanovaccine BNT162b, the trimerized confirmation of SARS-CoV-2 RBD and pre-fused confirmation of S protein are maintained and secreted from the nanoformulation to allow induction of broadly neutralizing antibodies [280] . Nanovaccines further offer advantage of sustained release of target antigen due to their enhanced lipophilicity [281] . In addition to the unique physicochemical characteristics, nanoparticles allow flexibility of surface engineering by incorporating cell-targeting peptides, proteins or polymers on their surface (Fig. 4) [282, 283] . Delivery of the antigen to the lymphatic system is the frontmost requirement for vaccine efficacy. Nanovaccines have ability to cross the intestinal space and reach the lymphatic tissue. Intranasal delivery of nanovaccine can easilty target the lymph nodes nearby the lung which would be advantageous for fighting against COVID-19 [283, 284] . Such properties make nanovaccines a versatile delivery vehicle for the treatment of COVID-19. (Fig. 2) [285, 286] . Multiple mRNAs can be combined into a single vaccine to deliver mRNA transcripts of interest into the host cell cytosol, which allows the encoding of one or more antigen(s). Such favourable properties designate mRNA vaccine as a forefront runner for the development against COVID-19 [21] . To note, no commercial vaccine is available till date developed with this technology which mandate strict regulatory requirments to undergo the candidate before approval for the general public. Mainly two types of mRNA constructs have been evaluated: self-amplifying mRNA and non-replicating mRNA [286] . Both types of mRNAs are synthetically produced, encoding target antigens' 5′ and 3′ untranslated region, cap structure, and open-reading frame, through the use of a cell-free enzymatic transcription reaction. Self-amplifying mRNA vaccines possess genetically-engineered replication machinery that is obtained from the positive-stranded mRNA viruses [286] . Delivery of the intact mRNA vaccine from the injection site to the target cell cytosol for the initiation of protein translation is as important as manufacturing of the mRNA construct. mRNA is labile and prone to degradation primarily from nuclease activity within the cells; hence, efficient protection of the mRNA is critical during administration [285] . Lipid nanoparticles could serve as safe and compatible intracellular delivery platform for the development of successful mRNA vaccine. Lipid nanoparticles offer (i) sustained mRNA confirmation (iii) protection J o u r n a l P r e -p r o o f of mRNA cargos against nuclease degradation and; (ii) efficient cellular uptake for targeted mRNA delivery [17, 276] . In the past, lipid nanocarrier system has delivered RNA for the therapeutic applications. In 2018, the first lipid nanoparticle formulated siRNA product Onpattro  was approved by the US FDA for the treatment of polyneuropathy caused by hereditary transthyretin-mediated amyloidosis, which established the standard for the clinical safety of lipid nanoparticle-based siRNA formulations [287] . Lipid nanoparticles are generally composed of ionizable lipids, cholesterol, PEGylated lipids, and phospholipids to deliver an mRNA construct. The ionizable cationic lipids create a lipid bilayer shell that allow mRNA encapsulation within an aqueous core for endosomal escape [288] . New-generation cationic lipids and lipoids are developed that maintain neutral or mild cationic charge at physiological pH to reduce nonspecific lipid-protein interactions [289] . Cholesterol provides stability to the lipid bilayer membrane and facilitates cellular transfection. PEGylated lipids serve to sterically stabilize the nanoparticles and reduce nonspecific protein bindings. Decoration of the outer surface with targerting moietires and encapsulation of multiples antigens for tailor-made immunization are additional advantages with lipid nanoparticles [290] . clinical trial results of BNT162b1 were available in August 2020 from 45 healthy adults of 18-55 years of age. Dose ascalation study was performed using 10μg, 30μg or 100μg of BNT162b1. 10μg and 30μg doses were given twice at 21 days interval while 100μg dose was given once due to increased risk of reactogenicity. Dose dependant RBDbinding IgG levels and SARS-CoV-2 neutralizing titers in the sera were detected at 21 days after the first dose that substantially increased after the second dose suggested robust immunogenicity in all participants. Geometric mean neutralizing titer levels were 1.8 to 2.8 fold higher than of COVID-19 convalescent human sera [296, 297] . The Vaccines must be stored in a narrow temperature range to maintain their stability and efficacy. Cold shipment chain for the vaccine, consumes almost 80% of the total vaccine development cost which limit vaccine access in the countries with low and emerging economies [303] . To overcone these challenges, a thermostable mRNA 

Similar protective immune responses were also observed in non-human primates (cynomolgus monkeys) after ARCoV immunization [306, 307] . ARCoV was found stable at different temperatures including 4°C, 25°C, and 37°C upto a week confirming its thermostability [308] .

An alphavirus-derived replicating RNA vaccine encoding the SARS-CoV-2 S protein, repRNA-CoV2S, was developed using lipid inorganic nanoparticles to enhance vaccine stability, immunogenicity, and targeted delivery. After a single or multiple intramuscular injections, repRNA-CoV2S induced robust SARS-CoV-2 S protein IgG antibodies and antigen-specific T cell responses in rodents and monkeys. Additionally, the neutralizing antibody responses were comparable to the COVID-19 convalescent plasma. The repRNA-CoV2S also induced robust immune responses in aged mice suggesting its potential for the elderly population. repRNA-CoV2S should be further evaluated in clinical studies to confirm its immunogenicity in humans [309] .

ii. Protein and subunit nanovaccine: Novavax Inc. is developing multiple nanoparticle vaccines for the COVID-19 treatment [310] . A promising candidate, recombinant SARS-CoV-2 full length S protein nanoparticle vaccine NVX-CoV2373 was generated by incorporating mutations at the S1 and S2 cleavage site to protect from proteolytic degradation and at the heptad repeat 1 site to maintain pre-fusion confugarations. NVX- other emerging coronavirus species (Fig. 5) . Both nanosponges were found safe upon J o u r n a l P r e -p r o o f intratracheal administration (300μg) which is very important to treat respiratory diseases including COVID-19. Overall, the nanosponge platform offers significant benefits over other therapies to fight against the rapidly mutating SARS-CoV-2 [314] .

A recombinant SARS-CoV-2 S1 subunit nanovaccine with two different adjuvants, amphiphilic adjuvant monophosphoryl lipid A (MPLA) and CpG oligiodeoxynucleotides (ODN) is developed. In mice, it induced robust humoral immune responses and strong CD4 and CD8 T cell activation compared to the free S1 subunit vaccine with traditional alum adjuvant.

Further studies are required to assess safety and clinical translatability of this nanovaccine for the COVID-19 treatment [315] . University of Washington School of Medicine researchers are developing a novel nanovaccine platfrom where viral antigen(s) is fused on the surface of self-assembling de novo designed nanoparticles that allow unprecedented molecular configuration control of the resulting vaccine [316] .

Researchers tailored self-assembling nanoparticles by presenting the ectodomains of influenza, HIV, and RSV viral glycoprotein trimers with the aim to induce better protective immune responses compared to direct antigen delivery [316] . Administration of HIV Env trimer-expressing nanoparticles in rhesus macaques showed accumulation of nanoparticles in the B cell follicles of the draining lymph nodes within two days after immunization, leading to enhanced protective immune responses [317] . As SARS-CoV-2 also exhibits trimeric S protein-like influenza, HIV, and RSV, researchers are developing a nanovaccine against COVID-19 using this technology [316] .

J o u r n a l P r e -p r o o f From various nanovaccine strategies, VLP is one of the preferred option with several advantages. VLPs are structurally identical to the virus particles, but lack viral genome. Therefore, VLPs are termed as non-replicating, and non-pathogenic viral capsid protein based vaccine [318] [319] [320] . VLPs can be either enveloped or nonenveloped. Enveloped VLPs contain viral proteins on their outer lipid membrane formed through budding from respective host cells, whereas non-enveloped VLPs lack lipid layers and are composed of one or more viral structural proteins [321] . VLPs can be decorated on their surface to display target antigen using recombinant fusion protein expression or chemical cross-linking with bifunctional linkers [322, 323] . adjuvants are frequenty employed in the VLP vaccines to improve immunogenicity in the older adults [324] [325] [326] [327] . VLPs engineered with multiple viral antigens can provoke the immune response against multiple viral strains [328] . Recently, VLPs are developed using plug-and-play technologies such as AviTag [329] and SpyCatcher/SpyTag [330] .

These technologies allow the conjugation of antigens through either reaction of biotin-J o u r n a l P r e -p r o o f streptavidin or the irreversible formation of an isopeptide. VLPs are potential vaccine candidates against diseases like malaria, dengue, and influenza [331, 332] . Additionally, the recombinant VLP based nanovaccines are already commercially available to protect against hepatitis B, hepatitis E, HPV, and porcine circovirus type-2 (PCV2) [333] . Such commercialy available VLP vaccines have already set a platfrom for the future vaccine candidates developed with this technology and relaxations in their regulatory requirments are expected. VLP vaccines generally carry small size viral epitopes that accommodate within the particle and therefore loading of larget epitopes such as HIV and influenza haemagglutinin are always challenging [334] .

In the past, VLP vaccines were produced from the human serum. The antigen expressing VLPs were isolated from the asymptomatic individuals with chronic viral infection. Although, the isolated VLPs were inactivated and purified, their safety is always uncertain [335] . Therefore, the eukaryotic expression systems are employed for the safe VLPs production. Recombivax HB ® and Engerix-B ® are recombinant VLP vaccines against HBV produced by Merck and GlaxoSmithKline, respectively. These VLP vaccines are produced from the Saccharomyces cerevisiae system that stabaly express hepatitis B virus surface antigen (HBsAg). The vaccines are safe and consist 20 nm size VLPs with octahedral symmetrical structure of the antigen [336] . The HPV prophylactic VLP vaccine Gardasil ® is synthesized by expressing HPV L1 capsid protein in S. cerevisiae (yeast). The HPV L1 protein self-assembles into immunogenic noninfectious VLPs with the 40-60 nm size, and can induce similar neutralizing antibody responses as the native virions [337] . Porcilis PCV ® is also a safe and effective

prophylactic VLP vaccine against PCV associated diseases, and is formed by the ORF2 J o u r n a l P r e -p r o o f capsid protein of PCV2 using the baculovirus expression system [338, 339] . The major disadvantages of the VLP vaccines produced from the a eukaryotic expression systems are that they offer low VLPs yield and expensive to scale-up and therefore such vaccine produce only partial immunity. As an alternative, mammalian expression systems are used for cost effective and large scale VLP vaccine development with the goal to incude better immune responses [322, 323] . A VLP vaccine Sci-B-Vac ® , exhibiting three HBV surface antigens S, pre-S1, and pre-S2, is produced from the mammalian Chinese hamster ovary (CHO) cells produces higher antibody titers against against HBV compared to the vaccines generated from the eukaryotic expression systems [340] . A hepatitis E virus (HEV) VLP vaccine Hecolin ® primarily consists of hepatitis E capsid protein that self assembles into 20-30 nm particles is prepared using a cost effective recombinant Escherichia coli expression system [341] . A recombinant HPV vaccine Cecolin ® is recently approved for marketing in China is also developed from Escherichia CpG 1018 or AS03 [348] . In preclinical testing, CoVLP vaccine induced high SARS-CoV-2 nutralizing antibody titers after a single adjuvanted dose [349, 350] . are under development [5, 22] . In order to achieve herd immunity and eliminate COVID-19, development of successful vaccines against SARS-CoV-2 using various technologies is highly desirable and certainly worth intensive consideration (Fig. 6) . Due vaccine has yet to achieve full US FDA approval [12] . Such a vaccine would protect atrisk individuals as well as curb the transmission of disease. Beyond the challenges of vaccine development and delivery, each vaccine requires rigorous testing to not only prove its' efficacy, but also to demonstrate its safety across mixed population. The WHO's criteria for vaccine prospects in Phase 2b/3 trials includes the vaccine's safety profile, potential for efficacy, stability, implementation, and availability. The specific criteria presented also revealed limitations and strengths of the different vaccines [10, 12] . The global nature of the pandemic and the disease's transmission are pushing such criteria to a more rigorous standard including, if at all possible, a single booster dose vaccination. The dosage will be critical as it will need to be potent enough to provide immune system priming, and thus control any viral 

Mass immunization through vaccination stands as the highest priority for control of the SARS-CoV-2 pandemic. Significant efforts are underway to complete this task and by the time of this publication, this goal will be on its ways towards a successful conclusion. Understandably, critical needs will remain and include how effective the chosen vaccine in the longer term and how to preclude adverse reactions. What underlies the immunological profiles for protective immunity and how long-lasting that immunity will be. Nonetheless, until these questions are addressed and a vaccine comes available parallel immune-based and pharmacological therapeutic options will be required to move forward with due diligence. While a many divergent vaccines and therapies are in the offering, full implementation is dependent on carefully-crafted clinical trial results and delivery. The bar to clear approvals for this task is high.

Obstacles include product safety, efficacy, and robust sustained antiviral immune 

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

World Health Organization, Naming the coronavirus disease (COVID-19) and the virus that causes it

Potential Indirect Effects of the COVID-19 Pandemic on Use of Emergency Departments for Acute Life-Threatening Conditions -United States

The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections

Cytokine storm intervention in the early stages of COVID-19 pneumonia

Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

COVID-19: immunopathogenesis and Immunotherapeutics

SARS-CoV-2 Vaccines: Status Report

World Health Organization, Draft landscape of COVID-19 candidate vaccines

On pins and needles: Will COVID-19 vaccines 'save the world

FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine

A strategic approach to COVID-19 vaccine R&D

Developing Covid-19 Vaccines at Pandemic Speed

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review

Research and Development on Therapeutic J o u r n a l P r e -p r o o f Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

Immunotherapeutic approaches to curtail COVID-19

Innovation Lessons From the COVID-19 Pandemic

Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

In silico and in vitro analysis of small molecules and natural compounds targeting the 3CL protease of feline infectious peritonitis virus

Hydroxychloroquine for the Prevention of Covid-19 -Searching for Evidence

Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know

Intracellular transport of class II MHC molecules directed by invariant chain

Hydroxychloroquine inhibits CD154 expression in CD4(+) T lymphocytes of erythematosus through NFAT, but not STAT5, signaling

Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells

Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines

The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor

CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation

Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8

Cutting edge: Antimalarial drugs inhibit IFN-beta production through blockade of cyclic GMP-AMP synthase-DNA interaction

Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer

Autophagy Is a Tolerance-Avoidance Mechanism that Modulates TCR-Mediated Signaling and Cell Metabolism to Prevent Induction of T Cell Anergy

Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option

Lack of antiviral activity of darunavir against SARS-CoV-2

Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo

GS-5734) for the Treatment of Ebola and Emerging Viruses

Remdesivir as a possible therapeutic option for the COVID-19

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial

SARS: systematic review of treatment effects

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis

Favipiravir: A new and emerging antiviral option in COVID-19

Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial, medRxiv

COVID-19 infection: the perspectives on immune responses

Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS

Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies

Convalescent plasma as a potential therapy for COVID-19

Emerging Therapeutic Potential of Mesenchymal Stem/Stromal Cells in Preeclampsia

Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use

Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study

Convalescent Plasma to Treat COVID-19: Possibilities and Challenges

Regeneron's COVID-19 antibody cocktail receives EUA from FDA

Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients

Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment

Regulatory T Cells for Treating Patients With COVID-19 and Acute Respiratory Distress Syndrome: Two Case Reports

Regulatory T Cells Tested in Patients With COVID-19 ARDS

Cellenkos Inc. Focuses on the Development of Cell-Therapy for Treatment of COVID-19 Mediated Acute Respiratory Distress Syndrome (CoV-ARDS)

Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS

Dysregulation of lung myeloid cells in COVID-19

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial

Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan

A systematic review of Anakinra, Tocilizumab, Sarilumab and Siltuximab for coronavirusrelated infections, medRxiv

Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

COVID-19: combining antiviral and anti-inflammatory treatments

COVID-19: risk for cytokine targeting in chronic inflammatory diseases?

Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell (GCLC) To Rapidly Develop COVID-19-Targeting Allogeneic NK Cell Combination Therapy

Neurological immunotherapy in the era of COVID-19 -looking for consensus in the literature

Herd Immunity: Understanding COVID-19

Herd immunity -estimating the level required to halt the COVID-19 epidemics in affected countries

Why do influenza virus subtypes die out? A hypothesis

Control of avian influenza in China: Strategies and lessons

Vaccination of poultry successfully eliminated human infection with H7N9 virus in China

The false promise of herd immunity for COVID-19

Vaccination and herd immunity to infectious diseases

Vaccination-induced herd immunity: Successes and challenges

COVID-19: Herd immunity and convalescent plasma transfer therapy

An interactive web-based dashboard to track COVID-19 in real time

Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand

Swedish policy analysis for Covid-19

Difficult to Determine Herd Immunity Threshold for COVID-19

Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance

Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study

Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications, medRxiv

Positive RT-PCR Test Results in Patients Recovered From COVID-19

A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma

COVID-19 reinfection or relapse: an intriguing dilemma

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

International Expansion of a Novel SARS-CoV-2 Mutant

Q&A: Influenza and COVID-19 -similarities and differences

Centers for Disease Control & Prevention, Estimated Influenza Illnesses, Medical visits, Hospitalizations, and Deaths in the United States -2019-2020 Influenza Season

More people have died from Covid-19 than in the past 5 flu seasons combined

Emergence of Novel Coronavirus and COVID-19: whether to stay or die out?

Immunobiology: The Immune System in Health and Disease. Infectious agents and how they cause disease

Chapter 2 -Virus Structure and Classification

Emerging viruses and current strategies for vaccine intervention

Toward an HIV vaccine: A scientific journey

Avoiding pitfalls in the pursuit of a COVID-19 vaccine

The COVID-19 vaccine development landscape

Vaccination strategies to combat novel corona virus SARS-CoV-2

The process development challenge for a new vaccine

Vaccines Through Centuries: Major Cornerstones of Global Health

Vaccines for the 21st century

Generation Vaccines

Immunisation Against Infectious Disease

Principles underlying rational design of live attenuated influenza vaccines

A review of vaccine development and research for industry animals in Korea

The double-edged sword: How evolution can make or break a liveattenuated virus vaccine

Live attenuated vaccines: Historical successes and current challenges

Fundamentals of vaccine immunology

Replication-defective viruses as vaccines and vaccine vectors

Preclinical safety testing of DISC-hGMCSF to support phase I clinical trials in cancer patients

Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection

Mechanisms of immunization with a replicationdefective mutant of herpes simplex virus 1

Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2

Immunobiology of influenza vaccines

Immunological mechanisms of vaccination

Attenuation of Human Respiratory Viruses by Synonymous Genome Recoding

Refining the balance of attenuation and immunogenicity of respiratory syncytial virus by targeted codon deoptimization of virulence genes

First Ebola vaccine approved

Pharmaceutical Technology, Indian Immunologicals, Griffith University to develop Covid-19 vaccine

Vaccine manufacturing: challenges and solutions

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials

s Genexine begins phase I/IIa trials for COVID-19 vaccine

Developments in Viral Vector-Based Vaccines, Vaccines (Basel)

Viruses -from pathogens to vaccine carriers

Viral vectors as vaccine platforms: deployment in sight

Self-Replicating RNA Viruses for RNA Therapeutics

Attenuated measles virus as a vaccine vector

A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes

A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV

Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination

Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines

A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity

Adenovirus vectors for gene therapy, vaccination and cancer gene therapy

Multivalent and Multipathogen Viral Vector Vaccines

Novel viral vectors in infectious diseases

Adenoviruses as vaccine vectors

Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors

Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial

Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines, Front Immunol

Basic biology of adeno-associated virus (AAV) vectors used in gene therapy

Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design

Novel adenoassociated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques

Engineering adeno-associated virus vectors for gene therapy

Singleshot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Safety and immunogenicity of an rAd26 and rAd5 vectorbased heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

The Russian vaccine for COVID-19

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind

CanSino's Covid-19 Vaccine Candidate Approved for Military Use in China

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind

AstraZeneca to supply Europe with up to 400 million doses of Oxford University's vaccine at no profit

Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines

Recent Advances in Subunit Vaccine Carriers, Vaccines (Basel

Biotechnology and the transformation of vaccine innovation: The case of the hepatitis B vaccines

Production and Purification of Recombinant Proteins from Escherichia coli

Production of Biopharmaceuticals in E. coli: Current Scenario and Future Perspectives

Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells

Production of recombinant proteins and metabolites in yeasts: when are these systems better than bacterial production systems?

New viral vaccines

Active and passive immunity, vaccine types, excipients and licensing

Treatment of acute nonchlamydial salpingitis. Study of the efficacy and tolerance of a single-therapy antibiotic: Augmentin

Recent Progress in Vaccine Development Against Chikungunya Virus

Immunogenicity and Efficacy Evaluation of Subunit Astrovirus Vaccines, Vaccines (Basel)

Commentary regarding: Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice

MigVax is developing an oral COVID-19 sub-unit vaccine

Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders

T cell responses in patients with COVID-19

Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial

Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation

Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation

Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy

Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology

Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease

Virusspecific CD8+ T cells upregulate programmed death-1 expression during acute friend retrovirus infection but are highly cytotoxic and control virus replication

Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment

PD-L1 Expression on Retrovirus-Infected Cells Mediates Immune Escape from CD8+ T Cell Killing

CRISPR-engineered T cells in patients with refractory cancer

Dendritic cell-based immunity and vaccination against hepatitis C virus infection

Dendritic cell-based vaccines: barriers and opportunities

Cell-Based Therapy for Severe COVID-19 Patients

Cellular vaccine approaches

Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer

Centers for Drug Control anf Prevention, Cell-Based Flu Vaccines

A treatment for COVID-19 will be found, reassures UM virologist

Adjuvants for Coronavirus Vaccines

Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses

A special issue on reviews in nanomedicine, drug delivery and vaccine development

Targeting the innate immune response with improved vaccine adjuvants

Approaches to tuberculosis mucosal vaccine development using nanoparticles and microparticles: a review

Vaccine adjuvants: current state and future trends

Advances in vaccine adjuvants

Current challenges for cancer vaccine adjuvant development

Vaccine immunopotentiators of the future

Toll-like receptor signalling

MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine

Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency

Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine

The recombinant Nterminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection, Vaccine

Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of

BALB/c mice immunized with UV-inactivated severe acute respiratory syndromerelated coronavirus vaccine

Aluminum vaccine adjuvants: are they safe?

Immunomodulatory properties of the vaccine adjuvant alum

Aluminum compounds as vaccine adjuvants

Vaccine adjuvant formulations: a pharmaceutical perspective

Mechanism of immunopotentiation and safety of aluminum adjuvants

A doubleinactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses

Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice

Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus

Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen

Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants

Structure-and oil type-based efficacy of emulsion adjuvants

Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity

MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination

Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59

The adjuvant MF59: the 1998 perspective, clinical performance and mechanism of action

SARS vaccine protective in mice

Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization

Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against

Middle East respiratory syndrome coronavirus

Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine

Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant

AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method

Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-inwater emulsion

Immunogenicity and protective efficacy in mice and hamsters of a betapropiolactone inactivated whole virus SARS-CoV vaccine

Efficacy of two adjuvant systems to promote humoral immunity to the pre-proghrelin peptide obestatin in pigs: consequences for the growth of piglets to weaning

Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators

A combined nucleocapsid vaccine induces vigorous SARS-CD8+

T-cell immune responses

Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Designing liposomal adjuvants for the next generation of vaccines

COVID-19 Vaccine Frontrunners and Their Nanotechnology Design

Recent Advances in Nanovaccines Using Biomimetic Immunomodulatory Materials, Pharmaceutics

Biodegradable particles as vaccine delivery systems: size matters

Exploring the role of polymer structure on intracellular nucleic acid delivery via polymeric nanoparticles

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Nanoparticle delivery systems in cancer vaccines

Engineering Antiviral Vaccines

Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients

Thermal-sensitive hydrogel as adjuvant-free vaccine delivery system for H5N1 intranasal immunization

The promise of mRNA vaccines: a biotech and industrial perspective

Mechanism of action of mRNA-based vaccines

Lipid Delivery Systems for Nucleic-Acid-Based-Drugs: From Production to Clinical Applications

Lipid-based nanoparticles for nucleic acid delivery

Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling

Blankschtein, mRNA vaccine delivery using lipid nanoparticles

Moderna Ships mRNA Vaccine Against Novel Coronavirus (mRNA-1273) for Phase 1 Study

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine

Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for

BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Pfizer and Biontech conclude Phase 3 study of covid-19 vaccine candidate, meeting all primary efficacy endpoints

UK authorises world's first Covid-19 vaccine

Pharmaceutical Business Review, Canada has approved Pfizer and BioNTech's mRNA vaccine BNT162b2 for the prevention of Covid-19

Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice

Temperature concerns could slow the rollout of new coronavirus vaccines

Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes

Rational design of cationic lipids for siRNA delivery

SARS-CoV-2 Infection in Children

Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model

A Thermostable mRNA Vaccine against COVID-19

An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates

Drug Development and Delivery

Novavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom

Novavax and Takeda Announce Collaboration for Novavax' COVID-19 Vaccine Candidate in Japan

Profile of a killer: the complex biology powering the coronavirus pandemic

Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity

Institute for Protein Design, De novo nanoparticles as vaccine scaffolds

Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations

Virus-like particles in vaccine development

Virus-like particles as particulate vaccines

More than one reason to rethink the use of peptides in vaccine design

Virus engineering: functionalization and stabilization

Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs

Recent Progress on the Versatility of Virus-Like Particles, Vaccines (Basel)

Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development

Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications

Induction of innate immunity in lungs with virus-like nanoparticles leads to protection against influenza and Streptococcus pneumoniae challenge

Construction and characterization of virus-like particles: a review

Virus-like particles: designing an effective AIDS vaccine

A Novel Virus-Like Particle Based Vaccine Platform Displaying the Placental Malaria Antigen VAR2CSA

Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization

A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies

Enveloped virus-like particle platforms: vaccines of the future?

Formulation and stabilization of recombinant protein based virus-like particle vaccines

Virus-like particles: passport to immune recognition

Newly licensed hepatitis B vaccine. Known safety and unknown risks

Antibody response to Engerix-B and Recombivax-HB hepatitis B vaccination in end-stage renal disease

Who invented the VLP cervical cancer vaccines?

One dose of a porcine circovirus 2 subunit vaccine induces humoral and cell-mediated immunity and protects against porcine circovirusassociated disease under field conditions

Synthetic biology for bioengineering virus-like particle vaccines

Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine

Virus-like particle-based human vaccines: quality assessment based on structural and functional properties

Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial

Improved Titers against Influenza Drift Variants with a Nanoparticle Vaccine

Preparation of virus-like particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells

Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice

Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV

Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV

Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Medicago's COVID-19 Vaccine Candidate with Dynavax's CpG 1018

Plant-based COVID-19 vaccine enters Phase I trials

Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-Two randomized Phase II clinical trials in 18 to 49 and >/=50 years old adults

A COVID-19 mRNA vaccine encoding SARS-CoV-2 viruslike particles induces a strong antiviral-like immune response in mice

Synthetic selfassembling ADDomer platform for highly efficient vaccination by genetically encoded multiepitope display

New vaccine platform used to develop COVID-19 candidates

Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19

Follow-up of asymptomatic patients with SARS-CoV-2 infection

Codiak BioSciences Collaborates with Ragon Institute to Evaluate the exoVACC™ Vaccine Platform in SARS-CoV-2 and HIV

Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults